We are dedicated to translating scientific breakthroughs into effective treatments for people with Alzheimer’s disease through cutting-edge research and comprehensive clinical trials.

This section provides access to scientific publications and congress presentations that have been shared with the research and medical community. These materials are made available to support scientific understanding and exchange and are presented as originally authored and delivered at scientific meetings or in peer‑reviewed journals. The presence of these materials on this website does not imply endorsement by the meeting organizers or publishers. Any products discussed therein are limited to investigational use only.

Explore a selection of our accomplished works, including:

2026

www
MANUSCRIPT 2026 Trials: Elucidating the phase 1 trial experience among study participants following completion of …
pdf
POSTER PRESENTATION  AAN 2026: Expected Centiloid Values for Patients with Positive Visual Reads of Amyloid …
pdf
PLATFORM PRESENTATION  ADPD 2026: Enhanced Brain Delivery of Sabirnetug After Fusion with an Anti-Transferrin Receptor …
pdf
POSTER PRESENTATION  ADPD 2026: Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with …
pdf
POSTER PRESENTATION  ADPD 2026: Sabirnetug Biomarker Treatment Responses: Exploratory Evaluation of the CNS Disease Panel …

2025

pdf
POSTER PRESENTATION  CTAD 2025: Fusing Transferrin Receptor Binders to the AβO-targeting Antibody Sabirnetug Achieves Increased …
pdf
POSTER PRESENTATION  CTAD 2025: ALTITUDE-AD: Recruitment strategies for a global phase 2 trial of sabirnetug …
70161
MANUSCRIPT 2025 TRCI: Recruitment and eligibility in a Phase 1 early Alzheimer’s disease trial of …
pdf
POSTER PRESENTATION  AAIC 2025: Sabirnetug shows superior selectivity for Aβ oligomers over monomer, a differentiated …
pdf
POSTER PRESENTATION  AAIC 2025: ALTITUDE-AD: Cost savings using a pTau217 screening assay in an ongoing …
pdf
POSTER PRESENTATION  AAN 2025: INTERCEPT-AD Biomarker Results: Early effect of sabirnetug treatment on synaptic biomarkers …
pdf
PLATFORM PRESENTATION  2025 AAN: ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in …
pdf
POSTER PRESENTATION  2025 ADPD: Utility of Human iPSC-derived Neuronal Model for Evaluating Synaptic Binding of …
pdf
POSTER PRESENTATION  2025 ADPD: Preparing Stable Monomeric Aβ to Assess AβO Selectivity Assays
pdf
PLATFORM PRESENTATION  ADPD 2025: ALTITUDE-AD: Use of a Validated Plasma pTau217 Assay to Screen Potential …
pdf
PLATFORM PRESENTATION  APDD 2025 Summit: Sabirnetug overview and use of a pTau217 Assay as a …
www
MANUSCRIPT  JPAD 2025: Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase …
www
MANUSCRIPT  JPAD 2025: INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild …

2024

pdf
PLATFORM PRESENTATION  CTAD 2024: ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants …
pdf
POSTER PRESENTATION  AAIC 2024: INTERCEPT-AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative …
pdf
POSTER PRESENTATION  AAIC 2024: Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase …
pdf
POSTER PRESENTATION  AAIC 2024: INTERCEPT-AD: Development and Qualification of a Highly Sensitive Immunoassay Detecting Total …
pdf
POSTER PRESENTATION  AAIC 2024:  INTERCEPT-AD: A Gender Analysis of the Phase 1 Experience Among Trial …
pdf
PLATFORM PRESENTATION  ADPD 2024: Sabirnetug (ACU193) Lowers CSF Neurogranin & pTau181 Levels in INTERCEPT-AD Study …
pdf
POSTER PRESENTATION  ADPD 2024:   Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring …
pdf
PLATFORM PRESENTATION  AAN 2024:   A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, …
pdf
POSTER PRESENTATION  AAN 2024:   A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, …

2023

pdf
POSTER PRESENTATION  CTAD 2023: Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A …
pdf
POSTER PRESENTATION  ADPD 2023:   Binding of Soluble Amyloid Beta Oligomer Species to Human IPSC-derived …
pdf
PLATFORM PRESENTATION  AAIC 2023:   Topline results of INTERCEPT-AD: A phase I trial of Aβ …
pdf
POSTER PRESENTATION  CTAD 2023:   INTERCEPT-AD phase 1 insights and findings from the investigation of …
pdf
POSTER PRESENTATION  CTAD 2023:   INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer’s disease.
pdf
POSTER PRESENTATION  CTAD 2023:   Incorporating the Study Participant’s Voice into Early Development of ACU193 …
pdf
POSTER PRESENTATION  CTAD 2023:   ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive …

2022

93
MANUSCRIPT  JPAD 2022:   ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development …
848215
MANUSCRIPT  Frontiers in Neuroscience 2022:   ACU193: An Immunotherapeutic Poised to Test the Amyloid β …
pdf
POSTER PRESENTATION  AAIC 2022:   Preparation and qualification of soluble AβOs for use in bioanalytical …
pdf
POSTER PRESENTATION  CTAD 2022:   Critical evaluation and comparison of biomarker values in commercial CSF …

2021

pdf
PLATFORM PRESENTATION  CTAD 2021:   Phase 1 trial design for ACU193, a monoclonal antibody that …

2019

pdf
POSTER PRESENTATION  AAIC 2019:   Soluble Aβ-Oligomer–Selective Antibody ACU3B3 Reduces Amyloid Pathology & Improves Multiple …
pdf
POSTER PRESENTATION  CTAD 2019: Synaptic intervention in Alzheimer’s disease: soluble Aβ oligomer directed ACU193 monoclonal …

2017

pdf
POSTER PRESENTATION  SfN 2017:   Oligomeric Ab-induced neuronal toxicity is attenuated by ADDL-specific antibodies in …

2014

pdf
POSTER PRESENTATION  SfN 2014: Soluble Aβ-oligomer-selective Antibody ACU-3B3 Reduces Amyloid Pathology and Improves Multiple Behavioral …
pdf
POSTER PRESENTATION  SfN 2014:   Passive immunization with the anti-Aβ oligomer antibody ACU-3B3 improves behavioral …